USP22 and metabolic dysfunction-associated steatotic liver disease: Enhanced expression of the deubiquitylating enzyme USP22 leads to SIRT1 deubiquitination and maintains its stability, which in turn activates the downstream autophagy signaling pathway, exerting a function in boosting fatty acid oxidation and inhibiting adipogenesis for the treatment of NAFLD (67, 68).